Key result
AngioVac achieves ~93% survival to discharge in right-sided infective endocarditis.
Why the study?
AngioVac is used for percutaneous vegetation removal in patients who are not surgical candidates, and this study aimed to characterize the demographics, echocardiographic features, indications, tricuspid regurgitation improvement, and survival outcomes reported in the literature.
Does percutaneous vegetectomy using the AngioVac system improve survival in patients with right-sided infective endocarditis who are poor surgical candidates?
Systematic Review (n=49)
Does percutaneous vegetectomy using the AngioVac system improve survival in patients with right-sided infective endocarditis who are poor surgical candidates?
Percutaneous vegetectomy using the AngioVac system is associated with high survival at discharge (93%) in critically ill patients with right-sided infective endocarditis who are poor surgical candidates.
Answers are grounded in this paper and cite their sources.
May support AngioVac in poor surgical candidates with right-sided IE; leaves open need for RCTs on long-term TR outcomes.
Backgrounds: AngioVac is used for the percutaneous removal of vegetations and for debulking of large vegetations in patients who are not surgical candidates.This study aims to identify the demographics, echocardiographic features, indications, improvement of the tricuspid valve regurgitation, and survival outcomes of patients who have undergone AngioVac vegetectomy reported in the literature. Methods: A systematic review was performed to identify articles reporting suction thromectomy or vegetation removal using the AngioVac system for RSIE (right sided infective endocarditis). Survival on discharge was our primary outcome. Additionally, we evaluated indications for suction thrombectomy and TR improvement. Categorical variables were expressed as percentages and ratios. Results: A total of 49 studies were identified. The most common risk factor was intravenous drug abuse seen in 45% (20/49) and cardiovascular implantable electronic device (CIED) in 45% (20/49). Circulatory shock was seen in 35% of patients. The causative organism was gram positive cocci (86%). Moderate to severe TR was present in 74% of cases with documented echocardiograms. Indications for AngioVac were poor surgical candidacy (81%) or to reduce septic emboli risk (19%). Survival at discharge was 93%. TR improvement was reported only in 16% cases and remained unchanged/worsened in 84%. Conclusion: AngioVac procedure is an alternative treatment for critically ill patients who cannot undergo surgery. To understand the survival, safety and candidacy of patients undergoing this procedure, further randomized control studies and literature reviews are needed. The improvement or worsening of tricuspid regurgitation in patients with TR valve involvement is another factor to be investigated.
No takes yet. Share an insight, caveat, or question.
Riasat et al. (2023) conducted a systematic review in Right-sided infective endocarditis (n=49). Percutaneous vegetectomy (AngioVac suction thrombectomy) was evaluated on Survival at discharge. AngioVac percutaneous vegetectomy achieved a 93% survival rate at discharge in patients with right-sided infective endocarditis, though tricuspid regurgitation improved in only 16% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: